Pharma & Biotech Mergers & Acquisitions News
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Pharmaceutical
Fibrosis drug developer Tvardi Therapeutics has hit the ground running after completing its merger with troubled US biotech Cara Therapeutics, inheriting a Nasdaq listing and a bolstered cash position. 14 May 2025
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Pharmaceutical
Shine Technologies, a private nuclear fusion corporation based in Wisconsin, USA, has entered into a definitive agreement to acquire the SPECT business from Lantheus, a radiopharmaceutical-focused company. 12 May 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Biotechnology
US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation. 8 May 2025
Pharmaceutical
Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug developer SpringWorks Therapeutics in the month's biggest buy, with Swiss firm Novartis the only other established big pharma name to acquire a company, though a host of further deals were done. 8 May 2025
Pharmaceutical
Japanese drugmaker Shionogi is to scale up its pipeline and global ambitions with a deal worth more than $1 billion, buying the pharmaceutical operations of Japan Tobacco, including its US subsidiary Akros Pharma. 8 May 2025
Pharmaceutical
US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, Regulus Therapeutics accepted a takeover bid from Swiss pharma giant Novartis worth a potential $1.7 billion. On the dealmaking front, US biotech Amicus Therapeutics acquired rights to Australian drug developer Dimerix’ kidney disease candidate DMX-200. Also of note, Eli Lilly had a setback, when the USA’s leading pharmacy benefits manager, CVS, said it will give Novo Nordisk’s weight loss product Wegovy priority over its Zepbound. 4 May 2025
Biotechnology
Shares in Kronos Bio, a US biotech that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, closed 20% lower Thursday. 2 May 2025
Pharmaceutical
Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in first-quarter 2025 from $18.8 billion in fourth-quarter 2024 to $37.7 billion. 2 May 2025
Pharmaceutical
Regulus Therapeutics saw its shares leap 133% to $7.84 in pre-market activity this morning, on the news it has agreed to be acquired by Swiss pharma giant Novartis. 30 April 2025
Biotechnology
USA-based Medicus Pharma has agreed to acquire UK firm Antev for around $75 milln in a share exchange deal. 28 April 2025
Pharmaceutical
After reported discussions since February, German pharma and sciences company Merck KGaA has confirmed its intension to acquire the US drug developer SpringWorks Therapeutics. 28 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Biotechnology
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 19 April 2025
Pharmaceutical
Florida biopharma Ligand Pharmaceuticals subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics, a developer of non-opioid pain treatments. 17 April 2025
Biotechnology
US gene therapy company bluebird bio announced that after three weeks of engagement, including a timeline extension, Ayrmid Pharma has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. 17 April 2025
Pharmaceutical
Dutch specialty pharma firm Norgine Pharmaceuticals has entered into a definitive agreement to acquire Theravia, a French pharmaceutical company specializing in cutting-edge treatments for patients with rare and debilitating conditions from Mérieux Equity Partners. 16 April 2025
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Pharmaceutical
Visiox Pharmaceuticals, a biopharma company based in Ohio, USA, has entered into a definitive merger agreement with Ocuvex Therapeutics. 20 August 2024
Pharmaceutical
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
Biotechnology
Last week’s news included second quarter financial results from BioNTech, the German mRNA biotech behind the successful covid vaccine Comirnaty, along with an update on its R&D pipeline. On the deal-making front, US biotech Equillium announced progress for its graft-versus-host disease drug itolizumab that is partnered with Japan’s Ono Pharmaceutical. Also, US gene editing firm Sangamo signed a licensing deal with Roche subsidiary Genentech that could earn it more than $2 billion. M&A news saw US firm Recursion enter a merger agreement with the UK’s Exscientia. Eli Lilly reported second quarter financial that beat expectations, driven by the performances of its new diabetes and obesity drugs. 11 August 2024
Biotechnology
US AI-enabled biotech Recursion and UK-based Exscientia today announced the companies have entered into a definitive merger agreement. 8 August 2024
Pharmaceutical
Denmark US oncology-based Pharmacosmos today revealed it has entered a definitive agreement to acquire US cancer-focused company G1 Therapeutics. 7 August 2024
Pharmaceutical
A quiet June gave way to a busier July in pharma M&A markets. 2 August 2024
Biotechnology
Japanese drugmaker Otsuka Pharmaceuticals is to buy privately-held US biotech Jnana Therapeutics. 1 August 2024
Pharmaceutical
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
Biotechnology
Tigermed (SZ: 300347), a global clinical research solution provider, has completed a move to boost capabilities in Japan and beyond, with the acquisition of the contract research organization (CRO) Medical Edge. 31 July 2024
Biotechnology
Boehringer Ingelheim today said it is taking a significant step in expanding its oncology pipeline of cancer cell-directed and immuno-oncology offering. 30 July 2024
Pharmaceutical
India’s Mankind Pharma has entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines (BSV) from Advent International. 26 July 2024
Pharmaceutical
US companies Palvella Therapeutics and Pieris Pharmaceuticals have agreed to merge in an all-stock transaction. 24 July 2024
Biotechnology
Agilent Technologies has signed a definitive agreement to acquire Biovectra, a leading specialized contract development and manufacturing organization (CDMO), for $925 million. 23 July 2024
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal has announced the acquisition of USA-based Valinor Pharma. 22 July 2024
Biotechnology
Shares in Legend Biotech (Nasdaq: LEGN) have climbed around 15% in recent days, after reports that the company has received a takeover offer. 15 July 2024
Biotechnology
M&A news last week featured US pharma major Eli Lilly announcing a $3.2 billion bid to acquire gastroenterology specialist Morphic. On the research front, US clinical-stage biotech HilleVax announced disappointing Phase IIb results with its norovirus vaccine HIL-214. Also, Dutch firm uniQure pleased investors with early--stage results for its investigational Huntington’s disease drug AMT-130, and US pharma gian
t Pfizer announced it is progressing its Parkinson’s disease candidate danuglipron. 14 July 2024
Pharmaceutical
UK-based liquid medicines maker Rosemont Pharmaceuticals says it has acquired Sabal Therapeutics along with its affiliates. 9 July 2024
Pharmaceutical
UK-based MedPharm, an Ampersand Capital Partners portfolio company, and the US firm Tergus Pharma, a Great Point Partners portfolio company, have jointly announced they are merging. 9 July 2024
Biotechnology
US pharma major Eli Lilly is to acquire Morphic (Nasdaq: MORF), a US biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, for $3.2 billion. 8 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze